MaxCyte, Inc. Sale of Stock, Consideration Received on Transaction
MaxCyte, Inc. (MXCT) reported Sale of Stock, Consideration Received on Transaction of $51.80 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-11-10.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2023-03-15
- MaxCyte, Inc. sale of stock, consideration received on transaction for the quarter ending 2021-03-31 was $51.80M.
| Period end | Sale of Stock, Consideration Received on Transaction 1 month | Sale of Stock, Consideration Received on Transaction 3 month |
|---|---|---|
| 2021-03-31 | $51.80M 10-Q · filed 2021-11-10 | |
| 2021-02-28 | $51.80M 10-K · filed 2023-03-15 | |
| 2019-03-31 | $12.30M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |